Epitopea

About

Epitopea is a transatlantic cancer immunotherapeutics company.

Cambridge,Cambridgeshire,United Kingdom
1 - 10

Highlights

Details

Last Funding Type: Seed
Last Funding Money Raised: £10.30M
Industries: Biotechnology,Life Science,Therapeutics
Founded date: Jan 1, 2021
Number Of Employee: 1 - 10
Operating Status: Active

Epitopea is a transatlantic biotechnology company developing transformational immunotherapies to treat cancer by targeting a new class of antigens that are broadly shared between patients with the same cancer indication. Cryptigen™ TSAs are discovered by a proprietary approach deploying immunopetidomics, mass spectrometry, genomics, and bioinformatics, which allows the identification of conserved, aberrantly-expressed, tumour-specific antigens, hidden in cancer's 'junk' DNA. These hidden Cryptigen™ TSAs have been identified by research led by Drs. Claude Perreault and Pierre Thibault at the Institute for Research in Immunology and Cancer at Université de Montréal.

Funding Rounds

Number of Funding Rounds

Total Funding Amount

1

£10.30M

Epitopea has raised a total of £10.30M in funding over 2 rounds. Their latest funding was raised on Apr 25, 2022 from a Seed round.

Announced Date	Round	Money Raised	Number of Investors	Lead Investors	Post Valuation
Apr 25, 2022	Seed	£10.30M	6	—	—	Detail

Investors

Number of Lead Investors

Number of Investors

—

6

Epitopea is funded by 6 investors. Cambridge Innovation Capital and Harrington Discovery Institute at University Hospitals are the most recent investors.

Investor Name	Lead Investor	Funding Round
Cambridge Innovation Capital	—	Seed
Harrington Discovery Institute at University Hospitals	—	Seed
Advent Life Sciences	—	Seed
CTI Life Sciences Fund	—	Seed
Fonds de solidarité FTQ	—	Seed
Novateur Ventures	—	Seed